Objective <p>This review focuses on the crystallization and cocrystallization of BCS Class II drug indomethacin (IMC), a common nonsteroidal anti-inflammatory drug (NSAID). In particular, it highlights the liquid antisolvent method as a viable strategy for creating IMC cocrystals with improved characteristics.</p> Significance of review <p>Indomethacin has a low bioavailability and poor water solubility, despite its therapeutic effectiveness. Cocrystallization has been a prominent approach to overcome these challenges. The liquid antisolvent method is thoroughly reviewed in this review, along with the physicochemical properties of indomethacin, together with other co-crystallization strategies to improve the physicochemical performance of IMC in pharmaceutical formulations.</p> Key findings <p>The review emphasizes that, in comparison to raw IMC, the crystals prepared by&#xa0;liquid antisolvent approach is a useful for enhancing IMC's crystal habit, solubility, dissolving rate, and bioavailability. Various solid forms, polymorphs, and cocrystal structures created throughout the process are also examined.</p> Conclusion <p>This review emphasizes the importance of cocrystallization and solid-form engineering, particularly the antisolvent approach, in enhancing the physicochemical properties. Solvents and coformers play a critical function. Integrating advanced characterization tools allows for optimizing formulations that helps poorly soluble medications get closer to improved bioavailability, clinical efficacy, and possible industrial use.</p>